Chaim Sheba Medical Center
Transcription-control mediated gene therapy blocks tumor angiogenesis
Published in FDA Law Weekly, June 10th, 2004
"A major drawback of current approaches to antiangiogenic gene therapy is the lack of tissue-specific targeting. The aim of this work was to trigger endothelial cell-specific apoptosis, using adenoviral vector-mediated delivery of a chimeric death receptor derived from the modified endothelium-specific pre-proendothelin-1 (PPE-1) promoter. In the present study, we constructed an adenovirus-based vector that targets tumor angiogenesis," researchers in Israel stated.
"Transcriptional control was achieved by use of a modified endothelium-specific promoter. Expression of a chimeric...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of FDA Law Weekly
Source: FDA Law Weekly (2004-06-10)
More Articles from FDA Law Weekly
- Adams Respiratory Therapeutics
FDA approves Mucinex DM extended-release tablets - American Pharmaceutical Partners
FDA accepts NDA for Abraxane for treatment of metastatic breast cancer - Angiolink Corporation
Device maker submits PMA for vascular closure system - Atrix Laboratories, Inc.
FDA grants approval to market fluticasone cream - Aventis
FDA approves new treatment for prostate cancer - BSD Medical Corp.
FDA approval granted to investigate new cancer treatment applicator - More from this issue of FDA Law Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
